Protara Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Protara Therapeutics, Inc. (TARA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $572.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-11
- Protara Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $289.00K, a 8.24% increase year-over-year.
- Protara Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $283.00K, a 7.60% increase year-over-year.
- Protara Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $278.00K, a 7.34% increase year-over-year.
- Protara Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $273.00K, a 7.48% increase year-over-year.
- Protara Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.08M, a 7.14% increase from fiscal 2024.
- Protara Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.01M, a 0.39% decline from fiscal 2023.
- Protara Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.01M, a 25.84% decline from fiscal 2022.
- Protara Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.37M, a 30.10% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $289.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $572.00K 10-Q · filed 2026-08-11 | $850.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $283.00K 10-Q · filed 2026-05-13 | $561.00K derived: sum of 2 quarters · filed 2026-05-13 | $834.00K derived: sum of 3 quarters · filed 2026-05-13 | $1.10M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $278.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $551.00K derived: sum of 2 quarters · filed 2026-03-10 | $818.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.08M 10-K · filed 2026-03-10 |
| 2025-09-30 | $273.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $540.00K derived: sum of 2 quarters · filed 2026-08-11 | $803.00K 10-Q · filed 2025-11-10 | $1.06M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $267.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $530.00K 10-Q · filed 2026-08-11 | $789.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.04M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $263.00K 10-Q · filed 2026-05-13 | $522.00K derived: sum of 2 quarters · filed 2026-05-13 | $776.00K derived: sum of 3 quarters · filed 2026-05-13 | $1.03M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $513.00K derived: sum of 2 quarters · filed 2026-03-10 | $763.00K derived: sum of 3 quarters · filed 2026-03-10 | $1.01M 10-K · filed 2026-03-10 |
| 2024-09-30 | $254.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $504.00K derived: sum of 2 quarters · filed 2025-11-10 | $750.00K 10-Q · filed 2025-11-10 | $1.05M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $250.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $496.00K 10-Q · filed 2025-08-11 | $798.00K derived: sum of 3 quarters · filed 2025-08-11 | $826.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $246.00K 10-Q · filed 2025-05-08 | $548.00K derived: sum of 2 quarters · filed 2025-05-08 | $576.00K derived: sum of 3 quarters · filed 2025-05-08 | $918.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $330.00K derived: sum of 2 quarters · filed 2025-03-05 | $672.00K derived: sum of 3 quarters · filed 2025-03-05 | $1.01M 10-K · filed 2025-03-05 |
| 2023-09-30 | $28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $370.00K derived: sum of 2 quarters · filed 2024-11-12 | $711.00K 10-Q · filed 2024-11-12 | $1.05M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $342.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $683.00K 10-Q · filed 2024-08-06 | $1.02M derived: sum of 3 quarters · filed 2024-08-06 | $1.37M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $341.00K 10-Q · filed 2024-05-02 | $683.00K derived: sum of 2 quarters · filed 2024-05-02 | $1.02M derived: sum of 3 quarters · filed 2024-05-02 | $1.37M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $342.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $683.00K derived: sum of 2 quarters · filed 2024-03-13 | $1.02M derived: sum of 3 quarters · filed 2024-03-13 | $1.37M 10-K · filed 2024-03-13 |
| 2022-09-30 | $341.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $683.00K derived: sum of 2 quarters · filed 2023-11-03 | $1.02M 10-Q · filed 2023-11-03 | $1.36M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $342.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $683.00K 10-Q · filed 2023-08-03 | $1.02M derived: sum of 3 quarters · filed 2023-08-03 | $1.33M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $341.00K 10-Q · filed 2023-05-04 | $679.00K derived: sum of 2 quarters · filed 2023-05-04 | $990.00K derived: sum of 3 quarters · filed 2023-05-04 | $1.34M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $649.00K derived: sum of 2 quarters · filed 2023-03-08 | $995.00K derived: sum of 3 quarters · filed 2023-03-08 | $1.05M 10-K · filed 2023-03-08 |
| 2021-09-30 | $311.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $657.00K derived: sum of 2 quarters · filed 2022-11-03 | $712.00K 10-Q · filed 2022-11-03 | $744.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $346.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $401.00K 10-Q · filed 2022-08-09 | $433.00K derived: sum of 3 quarters · filed 2022-08-09 | $455.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $55.00K 10-Q · filed 2022-05-05 | $87.00K derived: sum of 2 quarters · filed 2022-05-05 | $109.00K derived: sum of 3 quarters · filed 2022-05-05 | $128.00K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $54.00K derived: sum of 2 quarters · filed 2022-03-09 | $73.00K derived: sum of 3 quarters · filed 2022-03-09 | $93.00K 10-K · filed 2022-03-09 |
| 2020-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $41.00K derived: sum of 2 quarters · filed 2021-11-04 | $61.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $39.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $20.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |